Zhejiang Kanglaite Pharmaceutical Co., Ltd., established by Prof. Li Dapeng, is a ?State Key High-tech Enterprise? . Covering an area of 7 hectares and a total floor space of 28,000 sq. m, the LVP production line and auxiliary equipment were introduced from Europe and USA. International GMP standard is strictly followed in production. We have 32 sales regional offices in China and 2 subsidiaries in Russia and USA.
As ?State Basic Drug? and ?State Medical Insurance Drug?, the company mainly produces botanical anticancer drug Kanglaite Injection (KLT) which is a novel dual-function and molecular targeted emulsion with active substance extracted from a TCM herb ?semen coicis?. KLT has remarkable function in inhibiting and killing cancer cells while strengthening immune function. It has significant effectiveness in controlling cancerous pain, resisting cachexia, preventing cancer metastasis and recurrence, improving KPS, QOL and MST and effectively prolonging patient survival.
KLT has full intellectual property. Its chemical component, process technology and application have obtained patent certificates from over 10 countries in the world. In 2001 FDA approved KLT to start clinical study in USA and the Russian Ministry of Health issued KLT registration certificate in December 2003 and launched in July 2004 in Russia with great success. And registration in Saudi Arabia, Yemen, Vietnam, Peru, Pakistan and Thailand, etc. have also been conducted from 2007.
We are seeking overseas agent to register, import and distribute KLT with preferential policy. Contact us NOW.
Anticancer Drug Seeks Overseas Agent
Kanglaite Injection (KLT) is a botanical anticancer drug prepared in emulsion form for intravenous use. It is produced by advanced technology with active substance from a herbal plant "semen coicis".
KLT has the following clinical advantages to cancer patients.
- Effectively kills cancer cells while remarkably improves immune capacity;
- Synergistic function when combined with chemotherapy or radiation therapy;
- Provides high energy nutrition to treat cachexia;
- Markedly relieves cancerous pain;
- Improves QOL, PPT and MST to prolong survival;
- With very slight adverse reaction
KLT has brought great benefits to over 600,000 cancer patients in 2,300 hospitals in China and become the market leader among all anticancer drugs in China in recent 4 years.
Approved by FDA, phase I trial of KLT was conducted in 2001at Huntsman Cancer Institute, Salt Lake City, Utah, USA with inspiring result. Its anti-neoplastic mechanisms have been reconfirmed at Johns Hopkings University, USA.
KLT clinical study in Russia began in January 2002 and ended in April 2003 with satisfactory outcomes. The registration certificate was issued from Russian Ministry of Health in Dec. 2003. KLT was launched in Russia in July 2005 with great success.